Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessing role of comorbidities in treatment selection for older patients with acute myeloid leukemia
    Meeting Abstract

    Grenet, J.; Easwar, N.; Jain, A. G.; Burkart, M.; Ma, X.; Christos, P.; Ritchie, E. K.; Samuel, M.; Kaner, J. D.; Canaani, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Transcriptomic and epigenomic landscape of hairy cell leukemia at single-cell resolution
    Meeting Abstract

    Eton, E. O.; Ganesan, S.; Murray, R. M.; Durham, B. H.; Park, J. H.; Abdel-Wahab, O.; Landau, D. A.
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose escalation and dose expansion, multicenter clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lomonitinib (ZE46-0134) in adults with FLT3-mutated relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Lin, T. L.; Koenig, K. L.; Swords, R. T.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; Blum, W.; Schiller, G. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings
    Meeting Abstract

    Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.; Mascarenhas, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-day (Arm B) schedule of venetoclax + azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U.; Huang, Y.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study
    Meeting Abstract

    Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Combined human and in vivo analyses implicate the critical importance of acute myeloid leukemia associated CD8 T cells and identifies their molecular dysfunction
    Meeting Abstract

    Chu, Y. E.; Cottam, M. A.; Potts, C. R.; Dickerson, K. M.; Jenkins, M. T.; Cartailler, J. A.; Lu, R.; Lee, S. C.; Levine, R. L.; Bowman, R. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TP53 alterations confer increased risk of leukemic transformation and worse survival as compared to high molecular risk mutations in patients with myeloproliferative neoplasms
    Meeting Abstract

    Handa, S.; Riazat-Kesh, Y. J. R. A.; Butterfield, R. J.; Sivakumar, G.; Venugopal, S.; McGovern, E.; Feld, J.; Tremblay, D.; Elghaity-Beckley, S.; Kremyanskaya, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Blachly, J. S.; Thirman, M. J.; Mannis, G. N.; Arellano, M. L.; DiPersio, J. F.; Traer, E.; Zwaan, C. M.; Shukla, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized PrECOG 0905 study in newly diagnosed FLT3 mutated AML
    Meeting Abstract

    Luger, S.; Chen, L.; Pratz, K. W.; Loghavi, S.; Perl, A. E.; Altman, J. K.; Redner, R. L.; Fathi, A. T.; Qasrawi, A.; Asch, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save